Paytient Launches New Prescription Benefits to Reduce Drug Costs for Employers and Employees
In a bid to address the escalating costs of prescription medications, Paytient has announced a significant expansion of its services aimed at helping both employers and employees manage rising healthcare expenses. As employers brace for an anticipated 10% increase in healthcare costs for 2026, largely attributed to soaring prescription drug prices, Paytient is strategically targeting the core challenges faced by companies and their workforce.
While the healthcare landscape has progressed in terms of medication affordability, a crucial element remains overlooked: the ability for patients to pay for their prescriptions at the pharmacy right at the point of sale. A recent report from IQVIA highlighted a staggering number — 98 million prescriptions abandoned at pharmacies in the U.S. last year. This trend highlights a crucial gap: while 89% of individuals may fill a prescription priced at $15, that figure drops dramatically to 53% when the cost is $35, exemplifying how even a modest price increase can deter patients from purchasing their required medications.
Recognizing this challenge, Paytient focuses on simplifying the payment process for healthcare. They aim to ensure that prescriptions, irrespective of their copay amounts, are affordable and accessible. Brian Whorley, the founder and CEO of Paytient, stated, "The more frequently we witness cash price transactions in healthcare, the quicker the market will adjust and bring prices down. Our partnerships with notable organizations like GoodRx and the Mark Cuban Cost Plus Drug Company enable us to set realistic expectations in the marketplace and create an accessible route for employees to manage their medical expenses."
By implementing innovative plan-sponsored payment solutions mandated in 2025 through the Medicare Prescription Payment Plan, nearly 56 million Americans will now benefit from out-of-pocket expenses being fully covered at the pharmacy. This initiative propels Paytient into the forefront of providing similar advantages specifically for employers and their employees. According to recently released data, 44% of American workers with workplace insurance have previously postponed or skipped their medications due to high upfront costs. However, Paytient's recent Employee Healthcare Affordability Report reveals a significant turnaround – around 56% of members adhered to their prescribed treatment plans due to the cost-smoothing provided by Paytient solutions.
A report from the Patient Advocate Foundation further illuminates this issue, revealing that patients engaged in a payment plan abandoned expensive therapies at significantly lower rates compared to those who were not. Medication nonadherence not only impacts the health of individuals but also incurs substantial costs for employers, averaging around $100 billion annually. As Dr. Trent Haywood, Chief Outcomes Officer at Paytient, eloquently put it, "Adherence is beneficial not only for patients but also for the entire healthcare system."
For many, medications coming with price tags in the hundreds, such as a GLP-1 drug at an out-of-pocket cost of $299, present immediate financial barriers. Paytient's new offerings permit users the flexibility to avoid the burden of immediate payment, fostering better adherence to their treatment plans. The focus is to facilitate patients leaving pharmacies with the required medications, rather than just promises to return when funds are available.
The expanded functionality will also benefit from strategic alliances that Paytient has formed with key players in the pharmaceutical field. Collaborations with GoodRx pave the way for cost-effective prescription options, where customers have access to thousands of pharmacies nationwide for discount prices on both brand name and generic drugs. Simultaneously, Mark Cuban Cost Plus Drug Company introduces a revolutionary direct-to-consumer model aimed at offering radically reduced prices for medications, eliminating unnecessary markups inherent in traditional pharmaceutical pricing structures.
The integration of GoodRx and Mark Cuban Cost Plus Drug Company’s offerings into Paytient's platform ensures that users receive the best possible cash-pay pricing coupled with flexible payment options, thereby reshaping the financial dynamics of prescription medications for employers and their staff. Consequently, this aligns perfectly with Paytient's expansive network of health plan partners including major providers like Anthem, Optum, Centene, Elevance, and Cigna, broadening planning options for clients.
For a deeper understanding of Paytient's new prescription benefits and to explore their full range of services, you can visit their official website at Paytient. With this pivotal enhancement of prescription benefits, Paytient reaffirms its commitment to making healthcare affordable and accessible, reinforcing its position as a leader in healthcare affordability solutions.
While the healthcare landscape has progressed in terms of medication affordability, a crucial element remains overlooked: the ability for patients to pay for their prescriptions at the pharmacy right at the point of sale. A recent report from IQVIA highlighted a staggering number — 98 million prescriptions abandoned at pharmacies in the U.S. last year. This trend highlights a crucial gap: while 89% of individuals may fill a prescription priced at $15, that figure drops dramatically to 53% when the cost is $35, exemplifying how even a modest price increase can deter patients from purchasing their required medications.
Recognizing this challenge, Paytient focuses on simplifying the payment process for healthcare. They aim to ensure that prescriptions, irrespective of their copay amounts, are affordable and accessible. Brian Whorley, the founder and CEO of Paytient, stated, "The more frequently we witness cash price transactions in healthcare, the quicker the market will adjust and bring prices down. Our partnerships with notable organizations like GoodRx and the Mark Cuban Cost Plus Drug Company enable us to set realistic expectations in the marketplace and create an accessible route for employees to manage their medical expenses."
By implementing innovative plan-sponsored payment solutions mandated in 2025 through the Medicare Prescription Payment Plan, nearly 56 million Americans will now benefit from out-of-pocket expenses being fully covered at the pharmacy. This initiative propels Paytient into the forefront of providing similar advantages specifically for employers and their employees. According to recently released data, 44% of American workers with workplace insurance have previously postponed or skipped their medications due to high upfront costs. However, Paytient's recent Employee Healthcare Affordability Report reveals a significant turnaround – around 56% of members adhered to their prescribed treatment plans due to the cost-smoothing provided by Paytient solutions.
A report from the Patient Advocate Foundation further illuminates this issue, revealing that patients engaged in a payment plan abandoned expensive therapies at significantly lower rates compared to those who were not. Medication nonadherence not only impacts the health of individuals but also incurs substantial costs for employers, averaging around $100 billion annually. As Dr. Trent Haywood, Chief Outcomes Officer at Paytient, eloquently put it, "Adherence is beneficial not only for patients but also for the entire healthcare system."
For many, medications coming with price tags in the hundreds, such as a GLP-1 drug at an out-of-pocket cost of $299, present immediate financial barriers. Paytient's new offerings permit users the flexibility to avoid the burden of immediate payment, fostering better adherence to their treatment plans. The focus is to facilitate patients leaving pharmacies with the required medications, rather than just promises to return when funds are available.
The expanded functionality will also benefit from strategic alliances that Paytient has formed with key players in the pharmaceutical field. Collaborations with GoodRx pave the way for cost-effective prescription options, where customers have access to thousands of pharmacies nationwide for discount prices on both brand name and generic drugs. Simultaneously, Mark Cuban Cost Plus Drug Company introduces a revolutionary direct-to-consumer model aimed at offering radically reduced prices for medications, eliminating unnecessary markups inherent in traditional pharmaceutical pricing structures.
The integration of GoodRx and Mark Cuban Cost Plus Drug Company’s offerings into Paytient's platform ensures that users receive the best possible cash-pay pricing coupled with flexible payment options, thereby reshaping the financial dynamics of prescription medications for employers and their staff. Consequently, this aligns perfectly with Paytient's expansive network of health plan partners including major providers like Anthem, Optum, Centene, Elevance, and Cigna, broadening planning options for clients.
For a deeper understanding of Paytient's new prescription benefits and to explore their full range of services, you can visit their official website at Paytient. With this pivotal enhancement of prescription benefits, Paytient reaffirms its commitment to making healthcare affordable and accessible, reinforcing its position as a leader in healthcare affordability solutions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.